Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
Clinical trial NCT05457257 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05457257
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-29
- Primary completion
- 2024-10-22
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.